Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Esoteric Testing Market 

5.1. COVID-19 Landscape: Esoteric Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Esoteric Testing Market, By Type

8.1. Esoteric Testing Market, by Type, 2023 2032

8.1.1 Infectious Diseases Testing

8.1.1.1. Market Revenue and Forecast (2020 2032)

8.1.2. Endocrinology Testing

8.1.2.1. Market Revenue and Forecast (2020 2032)

8.1.3. Oncology Testing

8.1.3.1. Market Revenue and Forecast (2020 2032)

8.1.4. Genetics Testing

8.1.4.1. Market Revenue and Forecast (2020 2032)

8.1.5. Toxicology Testing

8.1.5.1. Market Revenue and Forecast (2020 2032)

8.1.6. Immunology Testing

8.1.6.1. Market Revenue and Forecast (2020 2032)

8.1.7. Neurology Testing

8.1.7.1. Market Revenue and Forecast (2020 2032)

8.1.8. Other Testing

8.1.8.1. Market Revenue and Forecast (2020 2032)

Chapter 9. Global Esoteric Testing Market, By Technology

9.1. Esoteric Testing Market, by Technology, 2023 2032

9.1.1. Chemiluminescence Immunoassay

9.1.1.1. Market Revenue and Forecast (2020 2032)

9.1.2. Enzyme-Linked Immunosorbent Assay

9.1.2.1. Market Revenue and Forecast (2020 2032)

9.1.3. Mass Spectrometry

9.1.3.1. Market Revenue and Forecast (2020 2032)

9.1.4. Real-Time PCR

9.1.4.1. Market Revenue and Forecast (2020 2032)

9.1.5. DNA Sequencing

9.1.5.1. Market Revenue and Forecast (2020 2032)

9.1.6. Flow Cytometry

9.1.6.1. Market Revenue and Forecast (2020 2032)

9.1.7. Other Technologies

9.1.7.1. Market Revenue and Forecast (2020 2032)

Chapter 10. Global Esoteric Testing Market, By End User 

10.1. Esoteric Testing Market, by End User, 2023 2032

10.1.1. Independent & Reference Laboratories

10.1.1.1. Market Revenue and Forecast (2020 2032)

10.1.2. Hospital-Based Laboratories

10.1.2.1. Market Revenue and Forecast (2020 2032)

Chapter 11. Global Esoteric Testing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2020 2032)

11.1.2. Market Revenue and Forecast, by Technology (2020 2032)

11.1.3. Market Revenue and Forecast, by End User (2020 2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.1.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.1.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.1.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.1.5.3. Market Revenue and Forecast, by End User (2020 2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2020 2032)

11.2.2. Market Revenue and Forecast, by Technology (2020 2032)

11.2.3. Market Revenue and Forecast, by End User (2020 2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.2.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.2.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.2.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.2.5.3. Market Revenue and Forecast, by End User (2020 2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2020 2032)

11.2.6.2. Market Revenue and Forecast, by Technology (2020 2032)

11.2.6.3. Market Revenue and Forecast, by End User (2020 2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2020 2032)

11.2.7.2. Market Revenue and Forecast, by Technology (2020 2032)

11.2.7.3. Market Revenue and Forecast, by End User (2020 2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2020 2032)

11.3.2. Market Revenue and Forecast, by Technology (2020 2032)

11.3.3. Market Revenue and Forecast, by End User (2020 2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.3.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.3.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.3.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.3.5.3. Market Revenue and Forecast, by End User (2020 2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2020 2032)

11.3.6.2. Market Revenue and Forecast, by Technology (2020 2032)

11.3.6.3. Market Revenue and Forecast, by End User (2020 2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2020 2032)

11.3.7.2. Market Revenue and Forecast, by Technology (2020 2032)

11.3.7.3. Market Revenue and Forecast, by End User (2020 2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.4.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.4.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.4.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.4.5.3. Market Revenue and Forecast, by End User (2020 2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2020 2032)

11.4.6.2. Market Revenue and Forecast, by Technology (2020 2032)

11.4.6.3. Market Revenue and Forecast, by End User (2020 2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2020 2032)

11.4.7.2. Market Revenue and Forecast, by Technology (2020 2032)

11.4.7.3. Market Revenue and Forecast, by End User (2020 2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.5.3. Market Revenue and Forecast, by End User (2020 2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2020 2032)

11.5.4.2. Market Revenue and Forecast, by Technology (2020 2032)

11.5.4.3. Market Revenue and Forecast, by End User (2020 2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2020 2032)

11.5.5.2. Market Revenue and Forecast, by Technology (2020 2032)

11.5.5.3. Market Revenue and Forecast, by End User (2020 2032)

Chapter 12. Company Profiles

12.1. ACM Global Laboratories (US)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. ARUP Laboratories (US).

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Baylor Esoteric and Molecular Laboratory (US)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. BioAgilytix Labs (US)

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. BP Diagnostic Centre SDN BHD (Malaysia)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. BUHLMANN Diagnostics Corp (BDC, US)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Cerba Xpert (Belgium)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Eurofins Scientific (Luxembourg)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Flow Health (US)

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Foundation Medicine (US)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms